AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Glifab 1mg/500mg Tablet SR

Prescription Icon
Prescription Required

Marketer

Biomorph Lifesciences

Salt Composition

Glimepiride (1mg) + Metformin (500mg)

Overview Glifab 1mg/500mg Tablet SR

DiabetaComb 1mg/500mg Extended-Release Tablets are classified as antidiabetic medications. This dual-action formulation treats type 2 diabetes in adults by regulating blood glucose. DiabetaComb should be ingested with meals, consistently at the same time daily for optimal efficacy. Dosage is determined and adjusted by your physician based on your blood sugar response. Continuous use is crucial; discontinuation without medical consultation risks elevated blood sugar, potentially leading to kidney complications, vision impairment, neuropathy, and limb loss. This medication is a component of a comprehensive diabetes management plan encompassing diet, exercise, and weight management as directed by your doctor. Lifestyle significantly impacts diabetes control. Hypoglycemia (low blood sugar) is the most frequent adverse effect, manifesting as sweating, dizziness, headache, or tremors. Regular meals and readily available glucose sources (e.g., sugary snacks, juice) are essential for prevention. Alcohol consumption should be minimized due to its potential to exacerbate hypoglycemia. Other possible side effects include altered taste, nausea, diarrhea, abdominal pain, headache, and upper respiratory infections. Weight gain may occur. This medication is contraindicated in type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Individuals with a history of heart disease should inform their physician before commencing treatment. Pregnant or lactating women require medical consultation prior to use. Regular blood glucose monitoring and potential blood tests (blood cell counts, liver function) are recommended by your doctor.

Uses of Glifab 1mg/500mg Tablet SR

Managing type 2 diabetes

Major Benefits of Glifab 1mg/500mg Tablet SR:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the entire tablet; avoid chewing, crushing, or fracturing it. It's recommended to take Glifab 1mg/500mg Sustained-Release Tablets with food.

Common Side effects of Glifab 1mg/500mg Tablet SR:

  • Headache
  • Hypoglycemia (low blood glucose level)
  • Nausea
  • Diarrhea

How to use Glifab 1mg/500mg Tablet SR:

Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment schedule. Ingest the entire tablet; avoid chewing, crushing, or fracturing it. It's recommended to take Glifab 1mg/500mg Extended-Release Tablets with a meal.

How Glifab 1mg/500mg Tablet SR works:

Glifab SR tablets (1mg glimepiride/500mg metformin) combine two distinct antidiabetic agents. Glimepiride, a sulfonylurea, stimulates pancreatic insulin secretion to reduce blood sugar. Metformin, a biguanide, acts by decreasing hepatic glucose output, retarding intestinal glucose uptake, and enhancing insulin responsiveness.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Glifab 1mg/500mg SR tablets with alcohol is inadvisable due to safety concerns.

PregnancyPregnancyCONSULT YOUR DOCTOR

The extended-release Glifab 1mg/500mg tablet may pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against possible risks prior to prescribing. Seek medical advice before use.

Breast feedingBreast feedingUNSAFE

Extended-release Glifab 1mg/500mg tablets are contraindicated for breastfeeding mothers. Evidence indicates potential infant toxicity from this medication.

DrivingDrivingCAUTION

Driving may be impaired by excessively low or high blood sugar levels. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should exercise caution when using Glifab 1mg/500mg Tablet SR, potentially requiring dosage modification. Consult your physician for guidance. Glifab 1mg/500mg Tablet SR is contraindicated in individuals with severe kidney disease. Routine monitoring of kidney function is recommended during treatment.

LiverLiverCAUTION

Patients with liver impairment should use Glifab 1mg/500mg Tablet SR cautiously, potentially requiring dosage modification. A physician's consultation is advised. For those with mild to moderate liver disease, initiation should be at a low dose; Glifab 1mg/500mg Tablet SR is contraindicated in cases of severe hepatic dysfunction.

What if you forget to take Glifab 1mg/500mg Tablet SR :

Should you forget a dose of your Glifab 1mg/500mg SR tablet, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Glifab 1mg/500mg Tablet SR

LabelValue
Addictive None.
Type of Medication Medication for diabetes

FAQs on Glifab 1mg/500mg Tablet SR

Maintain this medication within its original, sealed container or packaging. Follow the storage guidelines printed on the packaging or label. Discard any leftover medication. Ensure it remains inaccessible to children, animals, and others.
Indeed, Glifab 1mg/500mg Tablet SR carries a risk of lactic acidosis, a serious medical condition resulting from excessive blood lactic acid. Also termed Metformin-associated lactic acidosis (MALA), this is an uncommon but potentially dangerous adverse effect of metformin, particularly concerning for individuals with pre-existing kidney impairment, advanced age, or significant alcohol consumption. Manifestations of lactic acidosis can encompass muscle aches or weakness, vertigo, fatigue, cold extremities, respiratory distress, nausea, emesis, abdominal discomfort, and bradycardia. The appearance of such symptoms necessitates immediate discontinuation of Glifab 1mg/500mg Tablet SR and prompt medical attention.
Glimepiride/Metformin 1mg/500mg extended-release tablets (e.g., Glifab) combine two antidiabetic agents to manage type 2 diabetes mellitus in adults. This dual therapy enhances glycemic control when coupled with a suitable diet and exercise regimen. Glimepiride stimulates pancreatic insulin secretion, thus reducing blood glucose. Metformin concurrently decreases hepatic glucose production and augments insulin responsiveness. This formulation is unsuitable for managing type 1 diabetes.
Glifab 1mg/500mg sustained-release tablets may cause common adverse reactions including low blood glucose, taste disturbances, nausea, abdominal pain, loose stools, and cephalalgia. Rare but potentially severe side effects such as lactic acidosis may occur. Prolonged administration can result in Vitamin B12 depletion.
Prolonged use of Glifab 1mg/500mg SR tablets can indeed lead to Vitamin B12 deficiency. This medication impairs the body's ability to absorb Vitamin B12 within the gastrointestinal tract. Untreated deficiency may result in anemia, neurological complications, including paresthesia in the extremities, generalized weakness, urinary dysfunction, cognitive impairment, and gait instability. To mitigate this risk, supplemental Vitamin B12 is recommended by some experts on an annual basis.
Indeed, Glifab 1mg/500mg SR tablets can induce hypoglycemia. Low blood sugar symptoms may present as nausea, headache, irritability, hunger pangs, sweating, lightheadedness, tachycardia, and feelings of anxiety or tremors. The risk increases with skipped or delayed meals, alcohol consumption, strenuous physical activity, or concomitant use of other antidiabetic medications. Consequently, consistent blood glucose monitoring is crucial. Carrying readily available simple sugars, such as glucose tablets, honey, or fruit juice, is advisable.
Combining Glifab 1mg/500mg SR tablets and alcohol is unsafe. This combination can cause dangerously low blood sugar (hypoglycemia) and raise the risk of lactic acidosis.
Glifab 1mg/500mg Tablet S...
39
MRP 48
18% off